P2Y12 receptor drugs for Atherosclerotic Cardiovascular Disease

2 tracked P2Y12 receptor drugs in the Atherosclerotic Cardiovascular Disease race. The class explanation lives on the P2Y12 receptor page; the full indication pipeline across every mechanism is on the Atherosclerotic Cardiovascular Disease page.

2 approved / phase 4

Head-to-head evidence: Cangrelor vs Ticagrelor

The roster

← all P2Y12 receptor drugs